Calvin Yeang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5233022/publications.pdf

Version: 2024-02-01

45	2,903	236925	243625
papers	citations	25 h-index	44 g-index

46	46	46	3113
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 2016, 134, 611-624.	1.6	396
2	Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature, 2018, 558, 301-306.	27.8	359
3	Oxidized Phospholipids, Lipoprotein(a),Âand Progression of CalcificÂAortic ValveÂStenosis. Journal of the American College of Cardiology, 2015, 66, 1236-1246.	2.8	295
4	Statin therapy increases lipoprotein(a) levels. European Heart Journal, 2020, 41, 2275-2284.	2.2	265
5	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, ATV0000000000000147.	2.4	207
6	â€˜LDL-Câ€™â€Š=â€ŠLDL-Câ€Š+â€ŠLp(a)-C. Current Opinion in Lipidology, 2015, 26, 169-178.	2.7	122
7	PCSK9 Association With Lipoprotein(a). Circulation Research, 2016, 119, 29-35.	4.5	99
8	Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. Circulation Research, 2020, 126, 1346-1359.	4.5	96
9	Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). Journal of Clinical Lipidology, 2016, 10, 594-603.	1.5	88
10	Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels. JAMA Cardiology, 2018, 3, 1212.	6.1	76
11	Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 2022, 79, 1035-1046.	2.8	65
12	Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. Journal of Lipid Research, 2021, 62, 100053.	4.2	62
13	Lipoprotein(a)-Associated Molecules AreÂProminent Components in Plasma andÂValve Leaflets in Calcific Aortic ValveÂStenosis. JACC Basic To Translational Science, 2017, 2, 229-240.	4.1	61
14	Reduction of myocardial ischaemiaâ€“reperfusion injury by inactivating oxidized phospholipids. Cardiovascular Research, 2019, 115, 179-189.	3.8	61
15	Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Current Opinion in Cardiology, 2016, 31, 440-450.	1.8	55
16	The domain responsible for sphingomyelin synthase (SMS) activity. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 610-617.	2.4	53
17	Relationship between â€œLDL-Câ€ estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. Journal of Clinical Lipidology, 2018, 12, 702-710.	1.5	53
18	Sphingomyelin synthase 2 (SMS2) deficiency attenuates LPS-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L430-L440.	2.9	42

#	Article	IF	Citations
19	Role of Phospholipid Transfer Protein in High-Density Lipoproteinâ€“ Mediated Reverse Cholesterol Transport. Current Atherosclerosis Reports, 2011, 13, 242-248.	4.8	42
20	Phospholipid Transfer Proteinâ€“Deficient Mice Absorb Less Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2014-2021.	2.4	39
21	PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a HumanÂAntibody Detects ClinicallyÂRelevant Atherothrombosis. Journal of the American College of Cardiology, 2018, 71, 321-335.	2.8	39
22	Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. Journal of Lipid Research, 2019, 60, 2082-2089.	4.2	35
23	Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis. Cardiovascular Drugs and Therapy, 2016, 30, 75-85.	2.6	31
24	Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease. Current Opinion in Hematology, 2022, 29, 1-7.	2.5	29
25	ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. Heart, 2020, 106, 738-745.	2.9	28
26	Lowâ€Ðensity Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events. Journal of the American Heart Association, 2020, 9, e016318.	3.7	26
27	Subcellular Targeting Domains of Sphingomyelin Synthase 1 and 2. Nutrition and Metabolism, 2011, 8, 89.	3.0	23
28	Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk. Journal of Clinical Lipidology, 2016, 10, 1389-1396.	1.5	20
29	Statins and increases in Lp(a): an inconvenient truth that needs attention. European Heart Journal, 2020, 41, 192-193.	2.2	20
30	Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions. Journal of Cardiovascular Translational Research, 2014, 7, 719-736.	2.4	18
31	Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling. Circulation Research, 2017, 120, 1050-1052.	4.5	14
32	Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes. International Journal of Cardiology, 2020, 315, 81-85.	1.7	13
33	The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia. Current Opinion in Lipidology, 2020, 31, 305-312.	2.7	11
34	The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting. Angiology, 2017, 68, 795-798.	1.8	10
35	Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis. Atherosclerosis, 2022, 349, 144-150.	0.8	9
36	Sphingomyelin biosynthesis: its impact on lipid metabolism and atherosclerosis. Clinical Lipidology, 2009, 4, 595-609.	0.4	8

#	Article	IF	Citations
37	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). Journal of Lipid Research, 2020, 61, 1263-1270.	4.2	8
38	Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement. Angiology, 2019, 70, 332-336.	1.8	6
39	Diet-induced lipid accumulation in phospholipid transfer protein-deficient mice: its atherogenicity and potential mechanism. Journal of Lipid Research, 2010, 51, 2993-3002.	4.2	4
40	HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a). Journal of Lipid Research, 2015, 56, 1241-1244.	4.2	2
41	Ancient Remedy for a Modern Disease. JACC Basic To Translational Science, 2020, 5, 50-52.	4.1	2
42	Abstract 14697: Novel Assays for Quantification of Lipoprotein-Associated (PCSK9-apoB, PCSK9-Lp(a)) Proprotein Covertase Subtilisin/Kexin Type 9 (PCKS9). Circulation, 2015, 132, .	1.6	2
43	The role of lipoprotein(a) in progression of renal disease: Causality or reverse causality?. Journal of Diabetes and Its Complications, 2016, 30, 755-757.	2.3	1
44	Molecular Imaging of Oxidation-Specific Epitopes to Detect High-Risk Atherosclerotic Plaques. , 2015, , 121-154.		0
45	Abstract 11456: Elevated Lipoprotein(a) is Associated with Statin Resistance. Circulation, 2021, 144, .	1.6	0